Atlas Trials

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

Clinical trial NCT03639948 · UNKNOWN

Trial details

NCT number
NCT03639948
Sponsor
University of Kansas Medical Center
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Triple-negative Breast Cancer
Start date
2018-09-04
Primary completion
2022-01-27
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.